IFX-1 low dose + IFX-1 high dose + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Granulomatosis With Polyangiitis (GPA)
Conditions
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Trial Timeline
Oct 15, 2018 → May 3, 2021
NCT ID
NCT03712345About IFX-1 low dose + IFX-1 high dose + Placebo
IFX-1 low dose + IFX-1 high dose + Placebo is a phase 2 stage product being developed by InflaRx for Granulomatosis With Polyangiitis (GPA). The current trial status is terminated. This product is registered under clinical trial identifier NCT03712345. Target conditions include Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03712345 | Phase 2 | Terminated |
Competing Products
9 competing products in Granulomatosis With Polyangiitis (GPA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| Rituximab | Roche | Approved | 85 |
| Rituximab | Roche | Phase 2 | 52 |
| Methylprednisolone + Prednisone + Rituximab | Roche | Approved | 85 |
| Avacopan + Placebo | Amgen | Phase 2/3 | 64 |
| Abatacept + placebo | Bristol Myers Squibb | Phase 3 | 76 |
| IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC) | InflaRx | Phase 2 | 44 |
Other Products from InflaRx
vilobelimab + PlaceboPhase 3
69
IFX-1 + BSC + BSC + IFX-1 + SOC + Placebo + SOCPhase 2/3
57
Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placeboPhase 2
44
IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)Phase 2
44
Cohort C: bevacizumab + Cohort C: placeboPhase 2
44